SPERM COUNT TEST MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The Global Sperm Count Test Market size was valued at US$ 517.5 million in 2023 and is expected to reach US$ 1,180.3 million by 2030, grow at a compound annual growth rate (CAGR) of 12.5% from 2023 to 2030. Sperm count tests are used to evaluate semen samples to determine the sperm concentration and motility. These tests assist in diagnosing male infertility issues. The growing incidence of infertility and rising awareness about fertility testing are the key factors driving the sperm count test market.

By test type, the WHO reference values segment accounted for the largest market share in 2022. WHO reference values are the most commonly used guidelines to interpret semen analysis results. This standardized methodology has enabled wide adoption of sperm count tests globally.

Sperm Count Test Market Regional Insights

• North America is expected to be the largest market for Sperm Count Test Market during the forecast period, accounting for over 30% of the market share in 2022. The growth of the market in North America is attributed to the high awareness regarding fertility, access to advanced healthcare infrastructure, and supportive government policies.
• The Europe market is expected to be the second-largest market for Sperm Count Test Market, accounting for over 25% of the market share in 2022. The growth of the market in is attributed to the rising focus on male infertility screening and increasing medical tourism for fertility treatments.
• The Asia Pacific market is expected to be the fastest-growing market for Sperm Count Test Market, with a CAGR of over 38.5% during the forecast period. The growth of the market in Asia Pacific is attributed to growing adoption of sperm tests, large patient pool, and improving healthcare expenditure.

 Figure 1. Global Sperm Count Test Market Share (%), By Region, 2023

 Sperm Count Test Market Drivers:

• Rising incidence of infertility and importance of early diagnosis: The rising incidence of infertility among couples globally is a major factor driving the sperm count test market. As per estimates, 8-12% of couples face difficulties conceiving. Male infertility accounts for 20-30% of infertility cases. Sperm count tests assist in early diagnosis of potential fertility issues in males. They provide vital insights about sperm count and motility to help diagnose male infertility factors. The growing importance of early testing and proactive fertility management is expected to increase adoption of sperm count tests going forward.
• Increasing availability and awareness of at-home sperm test kits: The growing availability of easy-to-use and accurate at-home sperm count testing kits is driving market growth. Companies are focusing on developing sperm count kits designed for convenient in-home use. These kits allow men to test sperm counts privately in the comfort of their homes. Direct-to-consumer fertility test kits by companies like Trak, SpermCheck, YO etc. have improved awareness and adoption of sperm count testing among men. Their discreet and affordable at-home testing capabilities make them appealing to customers. The rising awareness and demand for at-home sperm tests provides growth opportunities for the sperm count test market.
• Advancements in sperm counting devices and methods: The integration of advanced technologies such as microfluidics, lab-on-chip, and AI in sperm analysis devices is enhancing speed, efficiency and accuracy. Companies are developing automated sperm counting systems and computer-aided sperm analysis (CASA) systems integrated with AI algorithms to perform rapid semen analysis and detect abnormalities. For instance, Medical Electronic Systems has CASA system - SCA CASA system which can assess sperm concentration and motility in under 1 minute. Such advancements are driving adoption and providing growth opportunities.
• Increasing fertility rates and access to fertility treatments: The rising fertility rates globally and increasing number of couples seeking fertility treatments is expected to drive the demand for sperm count testing. Around 2% of all babies born in the US are conceived using assisted reproductive technologies like IVF. Sperm analysis is routinely required before procedures like IVF, IUI etc. The growing access to fertility treatments and procedures especially in emerging economies will spur the adoption of sperm count testing.

Sperm Count Test Market Opportunities:

• Significant growth potential in emerging economies: Emerging economies present significant growth opportunities for sperm count test market owing to the large population base, rising infertility rates and improving healthcare expenditure. Countries like China, Brazil, Mexico and India have high infertility rates ranging from 10-15%. The low awareness, social stigma and high cost have limited adoption of sperm tests. Companies can focus on improving awareness and access to cost-effective tests in these untapped markets. Local partnerships, targeted marketing and region-specific products can help tap the high growth potential.
• Growing demand for fertility treatments and sperm banks: The rising number of couples opting for fertility treatments like IVF, IUI, and growth in fertility tourism provides opportunities for sperm count testing. Sperm count assessment is routinely required before fertility procedures. The increasing number of fertility clinics and rising procedures will drive testing volumes. Similarly, the growing number of sperm banks globally will also aid market growth. Increasing social acceptance, innovations like vitrification and need for donor eggs/sperm for IVF procedures will drive growth.
• Increasing applications of sperm function testing: Advancements in biomarkers and omics platforms have expanded the capabilities of sperm function testing beyond sperm count. Tests providing insights about DNA fragmentation, oxidative stress, apoptosis, ATP levels, sperm proteome etc. allow comprehensive assessment of male reproductive health and disorders. Their ability to provide actionable insights about lifestyle changes and treatment interventions presents growth opportunities. Increasing R&D and clinical validation will support adoption among clinicians and patients.
• Rise of fertility and health tracking apps: The emerging popularity of fertility tracking mobile apps provides opportunities for the integration of sperm testing and analysis. Apps allowing women to track ovulation, menstrual cycles and fertility hormones have gained immense popularity. The rise of male fertility tracking apps will also propel at-home sperm testing. Partnerships with app developers can help engage consumers with holistic trackers, remote analysis by clinicians and personalized recommendations to improve sperm parameters.

 Sperm Count Test Market Trends:

• Increasing consolidation activities among market players: The sperm count test market has witnessed increasing consolidation over the past few years. Established industry players are focused on inorganic strategies like acquisitions and partnerships to expand product portfolios, enter new markets and enhance distribution capabilities. For instance, Clinical Genetics expanded direct-to-consumer offerings with the acquisition of Halotech DNA's SpermCheck product. UEBE Medical partnered with Aska Pharmaceuticals to distribute YO Home Sperm Tests in Europe. Such consolidation activities are expected to rise, leading to expansion of leading players.
• Growing emphasis on developing enhanced sperm function assays: Research efforts to develop novel sperm function assays to evaluate parameters beyond routine semen analysis are rising. Technologies to assess DNA fragmentation, sperm membrane integrity, oxidative stress biomarkers, sperm metabolomics and proteomics to identify male infertility biomarkers are gaining prominence. For instance, Episona's Seed test provides information on sperm chromatin structure and DNA integrity. Additionally, the integration of lab automation and microfluidics for rapid sample processing and analysis has enabled development of enhanced assays. Their clinical value in conjunction with traditional semen analysis will support adoption.
• Increasing partnerships between industry players and fertility clinics/research institutes: Collaborations between industry players offering sperm test products/services and fertility clinics, hospitals and research institutes are increasing. These partnerships aim to conduct research studies, clinical validation of novel assays, evaluate new devices/platforms and expand patient access to testing. For instance, Sandstone Diagnostics partnered with UCSF for a male fertility study. MotilityCount collaborated with Rigshospitalet fertility clinic to validate its sperm quality test. Such partnerships allow companies to collect real-world evidence and support product development.
• Growing adoption of advanced automated sperm analyzers: Advanced automated sperm quality analyzers integrated with AI, multi-parameter analysis and techniques like CASA (computer-assisted sperm analysis) are gaining adoption. They allow rapid and standardized semen analysis by minimizing errors and variability. Companies like Medical Electronic Systems, Vitrolife, Microptic S.L. Offer automated sperm analyzers for clinical use. Their ability to assess multiple sperm parameters helps clinicians diagnose male infertility factors accurately. Automation aids workflow efficiency. The continued product development will support adoption among labs and clinics.

Sperm Count Test Market Restraints:

• High costs of testing devices and low reimbursements: The high costs of technologically advanced automated sperm counters and semen analysis systems leads to significant capital investments for procurement. Their high cost of ownership limits purchase and adoption among small clinics and hospitals with budget constraints. Additionally, variability in insurance coverage and reimbursement for fertility testing across regions also limits affordability. Low reimbursements in emerging economies restrict market growth to an extent.
• Stigma associated with infertility and semen analysis: The stigma, embarrassment and privacy concerns associated with fertility testing among men remains a key market challenge. Semen analysis requires masturbation at a clinic, which many men are uncomfortable with. Social stigma regarding sexual health and conservative attitudes about male infertility impact willingness to undergo testing in several countries. Lack of dialogue about fertility issues and low awareness limits open discussions. Though initiatives around men's health help, considerable efforts are needed to normalize testing.
• Stringent regulatory requirements: The sperm count test products and services need to meet stringent safety and performance standards set by regulatory agencies before commercialization. Device approvals, product registrations and clearances impose significant timelines. Authorities like U.S. FDA, EU CE, China's NMPA have technical specifications covering sample collection methodologies, adequacy of clinical evidence, software validations etc. Further, manufacturing, lab testing and quality regulations necessitate investments. The regulatory policies make product development and commercialization challenging.

Recent Developments

New product launches

• In January 2022, Halotech DNA announced the launch of SpermCheck, an at-home sperm count testing kit. This provided men with a convenient option to test sperm count privately at home.
• In June 2021, Trak Fertility launched Trak Male Fertility Testing System for sperm count and motility assessment. It enables rapid and accurate male fertility testing.
• In May 2020, Prestige Consumer Healthcare launched SpermCheck Fertility, an at-home sperm count testing kit providing results in 10 minutes. It made fertility testing accessible to more men.

Acquisition and partnerships

• In May 2022, Clinical Genetics announced the acquisition of Halotech DNA including its SpermCheck product strengthening its male fertility portfolio.
• In December 2021, UEBE Medical partnered with Aska Pharmaceuticals to distribute its YO Home Sperm Test in Europe improving access to at-home sperm analysis.
• In October 2020, Sandstone Diagnostics partnered with Medical Electronic Systems to expand distribution of its Trak Male Fertility system in the Middle East and Africa.

Figure 2. Global Sperm Count Test Market Share (%), By Type, 2023

Top companies in Sperm Count Test Market

• LLC Medical Group
• Abbot Laboratories
• CooperSurgical, Inc.
• Hamilton Thorne Ltd.
• Medical Electronic Systems
• Microptic S.L.
• ContraVac INC
• MotilityCount Aps
• DNA Diagnostics Center
• Prestige Consumer Healthcare
• Sandstone Diagnostics
• bioMerieux SA
• ASKA Pharmaceuticals
• Clinical Genetics Pty Ltd
• Halotech DNA
• SAS MARKit
• Trak Fertility
• UEBE Medical GmbH
• Vitrolife
• Welling Home Health

Definition: The sperm count test market refers to the industry and companies involved in manufacturing and supplying products, equipment and services used to evaluate and test semen samples to determine sperm count and motility. It includes products like sperm count test kits, instruments and software used by hospitals, clinics, cryobanks and home care settings to assess male fertility. The sperm analysis aids in diagnosing potential causes of male infertility. The market has grown steadily due to rising rates of infertility and adoption of fertility treatments globally.

Few other promising reports in Clinical Diagnostic Industry

Anal Fissure Treatment Market

Esoteric Testing Market

Legionella Testing Market

Salmonella Testing Market